

**IN THE CLAIMS:**

- 1.-8. (Canceled)
9. (Cancel) ~~Topical and systemic treatment of psoriasis patients with precursor molecules of epidermal growth factor, such as fibroblast growth factor.~~
10. (Cancel) ~~Treatment with products, with similar biological action as EGF, such as urogastrone or fractions of the EGF molecule.~~
11. (Currently Amended) A method for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation,  
  
wherein said formulation comprises epidermal growth factor as the sole active agent, and wherein the patient is a human being.
12. (Previously Added) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.01 to 50 micrograms/gram formulation.
13. (Previously Added) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.5 to 20 micrograms EGF/gram formulation.
14. (Previously Added) The method according to claim 11, wherein the formulation further comprises an anti-inflammatory product.
15. (Currently Amended) The method according to claim 4411, wherein the formulation is a topical cream containing 0.1 to 3% (w/w) of sulfadiazine and 0.5 to 20 micrograms EGF/gram formulation.
16. (Currently Added) The method according to claim 4415, wherein the

Applicant: Rudi D. NEIRINCKX  
Application No. 09/584,978  
Attorney Docket No. 2502491-991110  
(formerly 44334)

formulation comprises 10 $\mu$ g EGF and 1% (w/w) sulfadiazine.

17. (Cancel) ~~A method for treating psoriasis in a patient in need thereof comprising the step of systemically administering 0.001 to 10 micrograms of EGF/kg body weight.~~